UY36195A - Amidas de benzoxazinona como reguladores del receptor mineralocorticoide - Google Patents
Amidas de benzoxazinona como reguladores del receptor mineralocorticoideInfo
- Publication number
- UY36195A UY36195A UY0001036195A UY36195A UY36195A UY 36195 A UY36195 A UY 36195A UY 0001036195 A UY0001036195 A UY 0001036195A UY 36195 A UY36195 A UY 36195A UY 36195 A UY36195 A UY 36195A
- Authority
- UY
- Uruguay
- Prior art keywords
- mineralocorticoid
- benzoxazinona
- amidas
- regulators
- receiver
- Prior art date
Links
- 239000002395 mineralocorticoid Substances 0.000 title 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 abstract 2
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 210000003038 endothelium Anatomy 0.000 abstract 1
- -1 of benzoxazinone amides Chemical class 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000004218 vascular function Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018790P | 2014-06-30 | 2014-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY36195A true UY36195A (es) | 2016-01-08 |
Family
ID=53539739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001036195A UY36195A (es) | 2014-06-30 | 2015-06-26 | Amidas de benzoxazinona como reguladores del receptor mineralocorticoide |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10017502B2 (OSRAM) |
| EP (1) | EP3160948B1 (OSRAM) |
| JP (1) | JP6368383B2 (OSRAM) |
| KR (1) | KR102012222B1 (OSRAM) |
| CN (1) | CN106536491B (OSRAM) |
| AR (1) | AR101036A1 (OSRAM) |
| AU (1) | AU2015282450C1 (OSRAM) |
| CA (1) | CA2953655C (OSRAM) |
| CY (1) | CY1121596T1 (OSRAM) |
| DK (1) | DK3160948T3 (OSRAM) |
| EA (1) | EA029518B1 (OSRAM) |
| ES (1) | ES2707726T3 (OSRAM) |
| HR (1) | HRP20190147T1 (OSRAM) |
| HU (1) | HUE042370T2 (OSRAM) |
| LT (1) | LT3160948T (OSRAM) |
| ME (1) | ME03316B (OSRAM) |
| MX (1) | MX367404B (OSRAM) |
| PL (1) | PL3160948T3 (OSRAM) |
| PT (1) | PT3160948T (OSRAM) |
| RS (1) | RS58274B1 (OSRAM) |
| SI (1) | SI3160948T1 (OSRAM) |
| SM (1) | SMT201900039T1 (OSRAM) |
| TR (1) | TR201900659T4 (OSRAM) |
| TW (1) | TWI677498B (OSRAM) |
| UY (1) | UY36195A (OSRAM) |
| WO (1) | WO2016001631A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3160948T3 (pl) * | 2014-06-30 | 2019-04-30 | Astrazeneca Ab | Amidy benzoksazynonu jako modulatory receptorów mineralokortykoidowych |
| MA53175A (fr) | 2018-07-19 | 2021-05-26 | Astrazeneca Ab | Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci |
| CN112107568B (zh) * | 2019-06-19 | 2022-03-25 | 北京龙嘉博创医药科技有限公司 | 二芳基酰胺类化合物及其应用 |
| SG11202003971RA (en) | 2019-08-30 | 2021-04-29 | Astrazeneca Ab | Methods of treating heart failure with reduced ejection fraction with dapagliflozin |
| PT4188389T (pt) | 2020-07-27 | 2025-10-07 | Astrazeneca Ab | Dapagliflozina para utilização em métodos de tratamento de doença renal crónica |
| BR112023025793A2 (pt) * | 2021-06-15 | 2024-02-27 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Composto de fórmula (ii), um estereoisômero deste ou um sal farmaceuticamente aceitável deste, composição farmacêutica e uso do composto |
| TW202409023A (zh) | 2022-07-14 | 2024-03-01 | 美商富曼西公司 | 除草苯并𠯤 |
| KR20250053191A (ko) | 2022-09-01 | 2025-04-21 | 아스트라제네카 아베 | 심장신장 질환의 치료에 사용하기 위한 sglt2 억제제 및 미네랄코르티코이드 수용체 조절제의 조합 |
| WO2024125591A1 (zh) * | 2022-12-15 | 2024-06-20 | 正大天晴药业集团股份有限公司 | 苯并恶嗪酮类化合物的结晶及其制备 |
| WO2025111184A1 (en) | 2023-11-21 | 2025-05-30 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002085868A1 (en) * | 2001-04-23 | 2002-10-31 | Astrazeneca Ab | Benzoxazinone derivatives for use in the treatment of angiogenesis |
| MXPA05006742A (es) * | 2002-12-20 | 2005-09-08 | Warner Lambert Co | Benzoxazinas y derivados de las mismas como inhibidores de fosfoinositido-3-quinasas. |
| BRPI0513119A (pt) * | 2004-07-14 | 2008-04-29 | Ligand Pharm Inc | compostos e métodos modulares de receptores intracelulares |
| AU2005267798A1 (en) | 2004-07-28 | 2006-02-09 | Irm Llc | Compounds and compositions as modulators of steroid hormone nuclear receptors |
| CA2635541A1 (en) | 2005-12-28 | 2007-07-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| ATE537151T1 (de) | 2006-10-31 | 2011-12-15 | Pfizer Prod Inc | Pyrazolinverbindungen als mineralocorticoidrezeptorantagonisten |
| DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
| US8063090B2 (en) | 2007-03-23 | 2011-11-22 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor modulators |
| WO2008126831A1 (ja) | 2007-04-09 | 2008-10-23 | Daiichi Sankyo Company, Limited | ピロール誘導体のアトロプ異性体 |
| JP5173653B2 (ja) * | 2007-08-01 | 2013-04-03 | 田辺三菱製薬株式会社 | 医薬組成物 |
| US8258131B2 (en) | 2007-08-01 | 2012-09-04 | Mitsubishi Tanabe Pharma Corporation | Fused bicyclic compound |
| PE20091057A1 (es) | 2007-12-19 | 2009-07-20 | Lilly Co Eli | Antagonistas del receptor mineralcorticoide y metodos de uso |
| JP2011524896A (ja) * | 2008-06-18 | 2011-09-08 | アストラゼネカ・アクチエボラーグ | 呼吸器障害の処置用のベータ２−アドレナリン受容体アゴニストとして作用するベンズオキサジノン誘導体 |
| US20100094000A1 (en) | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
| WO2010098286A1 (ja) | 2009-02-25 | 2010-09-02 | 第一三共株式会社 | ミネラルコルチコイド受容体拮抗薬を含有する医薬 |
| BRPI1009257A2 (pt) | 2009-03-12 | 2016-03-08 | Lilly Co Eli | antagonista receptor de mineralocorticoide e métodos de uso. |
| WO2010116282A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | 4, 5-dihydro-lh-pyrazole compounds and their pharmaceutical uses |
| WO2011141846A2 (en) | 2010-05-11 | 2011-11-17 | Koninklijke Philips Electronics N.V. | Lighting module |
| EP2569310A1 (en) | 2010-05-11 | 2013-03-20 | Pfizer Inc | Morpholine compounds as mineralocorticoid receptor antagonists |
| JPWO2012008435A1 (ja) | 2010-07-13 | 2013-09-09 | 大日本住友製薬株式会社 | ビアリールアミド誘導体またはその薬理学的に許容される塩 |
| JP2013542255A (ja) | 2010-11-10 | 2013-11-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ミネラルコルチコイド受容体アンタゴニストとしてのピリジル尿素 |
| PL3160948T3 (pl) * | 2014-06-30 | 2019-04-30 | Astrazeneca Ab | Amidy benzoksazynonu jako modulatory receptorów mineralokortykoidowych |
-
2015
- 2015-06-26 PL PL15736015T patent/PL3160948T3/pl unknown
- 2015-06-26 MX MX2017000183A patent/MX367404B/es active IP Right Grant
- 2015-06-26 DK DK15736015.7T patent/DK3160948T3/en active
- 2015-06-26 LT LTEP15736015.7T patent/LT3160948T/lt unknown
- 2015-06-26 HU HUE15736015A patent/HUE042370T2/hu unknown
- 2015-06-26 UY UY0001036195A patent/UY36195A/es not_active Application Discontinuation
- 2015-06-26 CN CN201580035032.8A patent/CN106536491B/zh active Active
- 2015-06-26 SM SM20190039T patent/SMT201900039T1/it unknown
- 2015-06-26 SI SI201530572T patent/SI3160948T1/sl unknown
- 2015-06-26 JP JP2016575499A patent/JP6368383B2/ja active Active
- 2015-06-26 PT PT15736015T patent/PT3160948T/pt unknown
- 2015-06-26 EA EA201790046A patent/EA029518B1/ru not_active IP Right Cessation
- 2015-06-26 TR TR2019/00659T patent/TR201900659T4/tr unknown
- 2015-06-26 ES ES15736015T patent/ES2707726T3/es active Active
- 2015-06-26 HR HRP20190147TT patent/HRP20190147T1/hr unknown
- 2015-06-26 RS RS20190085A patent/RS58274B1/sr unknown
- 2015-06-26 ME MEP-2019-19A patent/ME03316B/me unknown
- 2015-06-26 KR KR1020177002518A patent/KR102012222B1/ko active Active
- 2015-06-26 CA CA2953655A patent/CA2953655C/en active Active
- 2015-06-26 AU AU2015282450A patent/AU2015282450C1/en active Active
- 2015-06-26 EP EP15736015.7A patent/EP3160948B1/en active Active
- 2015-06-26 WO PCT/GB2015/051860 patent/WO2016001631A1/en not_active Ceased
- 2015-06-26 US US15/320,379 patent/US10017502B2/en active Active
- 2015-06-29 TW TW104120998A patent/TWI677498B/zh active
- 2015-06-29 US US14/753,239 patent/US9394291B2/en active Active
- 2015-06-30 AR ARP150102098A patent/AR101036A1/es active IP Right Grant
-
2019
- 2019-01-24 CY CY20191100097T patent/CY1121596T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY36195A (es) | Amidas de benzoxazinona como reguladores del receptor mineralocorticoide | |
| DOP2018000268A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| CL2018003681A1 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos | |
| UY36342A (es) | Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos | |
| CO2017012995A2 (es) | Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos | |
| CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| CR20170384A (es) | Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| UY35485A (es) | Compuestos heterocíclicos y usos de los mismos | |
| CL2016001973A1 (es) | Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
| NI201700129A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa. | |
| MX2017009505A (es) | Derivados de 9h-pirrolo-dipiridina. | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| UY36003A (es) | Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina. | |
| DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| CR20160460A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| GT201700058A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| UY35947A (es) | Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen | |
| ECSP16096831A (es) | Derivados de naftiridinadiona | |
| CR20170090A (es) | Derivados de terahidroquinolina como inhibidores del bromodominio | |
| MX377506B (es) | Ureas asimetricas p-sustituidas y usos medicos de las mismas. | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| UY37191A (es) | Derivados de dibenzofurano para uso como inhibidores de bromodominio |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20201204 |